Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Companies

Set Alert for Companies

Market Intel: Apps for Epilepsy, Steps for Health, Meditation Guides, Mouth Labs Cross Digital Divide For Better Health

Startups at the convergence of technology and biomedical innovations showcased compelling innovations at this week's Exponential Medicine conference in San Diego. This article offers a roundup of new devices targeting a wide range of applications from neurology, cardiology, chronic diseases and wellness.

Innovation Analysis Commercial
Advertisement

Latest From Companies

QUOTED. Nov. 13, 2018. Avi Fischer.

Abbott Laboratories pointed to success in its electrophysiology device business last quarter, driven by multiple products including the Confirm Rx insertable cardiac arrhythmia monitor, which the firm says is the thinnest in class, and is smartphone-compatible for more direct patient engagement. See what Abbott VP Ari Fischer says about it here.

Quoted Commercial

Q3 Earnings Spotlight: Ortho Firms Show Mixed Results Against US Pricing Pressure

Reported sales and earnings from the publicly traded orthopedics device companies showed mix results during the third quarter of 2018. NuVasive was the star performer in the group while, on the other end of the spectrum, Stryker continued to show strong growth across most its businesses, while Johnson & Johnson's orthopedic device revenue was near flat.</p>

Orthopedics Deals

Q3 Earnings Spotlight: Roche, Abbott, bioMérieux Lead IVD Company Results

Medtech Insight highlights Q3 2018 results from some of the leading IVD players. In this edition, we spotlight some of the big companies including Roche Diagnostics, Thermo Fisher Scientific, bioMérieux, and Becton Dickinson.

Commercial In Vitro Diagnostics

QUOTED. Nov. 9, 2018. Pete DeComo.

When ALung Technologies was selected in 2015 by US FDA to participate in the agency's Expedited Access Pathway program for its novel Hemolung device, the firm wasn't necessarily sure what it was getting itself into. See what ALung CEO Pete DeComo said about the pathway – now called the Breakthrough Devices Program – here.

Quoted Respiratory

Q3 Earnings Spotlight: Abiomed Shines Among Cardiology Device-Makers

Reported sales and earnings from the publicly traded cardiovascular device companies show strong performance across the sector, spurred by new approvals and clinical trials, in the quarter that ended Sept. 30. Here's a recap of results from the cardio device companies that have reported so far, including Abbott, Abiomed, and Reva.

Commercial Cardiovascular

Stryker To Settle Hip Implant Suits

Stryker and plaintiff attorneys are hashing out an agreement to settle thousands of lawsuits brought by patients who say they were injured by the device-maker's hip implants.

Legal Issues Commercial

Medtech Money Flow: M&A And VC Deals, Oct. 29-Nov. 4, 2018

This edition of Medtech Money Flow rounds up the M&A and venture financing deals, as recorded in our M&A and VC Deal Trackers, between Oct. 29 and Nov. 4, 2018.  

M & A Financing

Device Week, Nov. 2, 2018 – Third-Quarter Earnings Report Update From IVD, Cardio, and Ortho Companies

On this week's podcast, Reed Miller and Catherine Longworth give an overview of the third-quarter earnings reports from the major public companies in the in vitro diagnostics, cardiovascular and orthopedics device sectors.

Device Week Business Strategies

Breathing Easy: ALung CEO Talks Novel Hemolung Device, FDA's Breakthrough Pathway, Landmark US/UK Clinical Trials

In a deep-dive sit-down interview with Medtech Insight, ALung Technologies CEO Pete DeComo dishes on US FDA's Breakthrough Devices Program and explains why his firm's novel artificial lung device, Hemolung, is worthy of traveling the expedited pathway to agency approval. DeComo also details two pivotal Hemolung clinical trials in the US and UK, and explains why Hemolung isn't marketing the device for commercial use despite being approved in 36 countries outside the US. He also talks about a future portable version of Hemolung, but noted that's not where ALung is focused right now. "Our first task is that first-generation technology – to get it to market, make it the standard-of-care, and then, if you are successful with all of that, you can do all of those wonderful other things as it relates to portability and wearability," DeComo says.

Respiratory Innovation
See All
UsernamePublicRestriction

Register